Currently, the availability of ICIs, such as anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) and anti-programmed cell death 1(PD-1)/programmed cell death-ligand 1 monoclonal antibodies, has significantly changed the approach to cancer treatment. The gene discussed is PDCD1; the disease is cancer.